GlobeNewswire·Aug 4, 2026, 8:00 AM ET

Exagen Inc. Reports Second Quarter 2026 Financial Results

Exagen Inc. reported record total revenue of $19.9 million for the second quarter of 2026, a 16% increase compared to the same period in 2025.
Full-year 2026 revenue guidance was increased to $72 million - $75 million from a previous range of $70 million - $73 million.
Net loss was reduced by nearly 30% to $3.2 million for the quarter, down from $4.4 million in the prior year period.
Adjusted EBITDA loss narrowed significantly to $0.1 million, compared to a loss of $1.7 million in the second quarter of 2025.
AVISE CTD test volume grew 11% year-over-year in the second quarter of 2026.
Trailing twelve-month average selling price (ASP) for AVISE CTD tests increased 4% to $446 per test.
The company ended the quarter with approximately $25 million in cash \& cash equivalents.
A systematic review of over 3,100 patients across 14 medical centers validated that AVISE CTD identified approximately 25% of SLE patients missed by conventional markers.
Six-month revenue for 2026 reached $37.2 million, up from $32.7 million in the same period of 2025.
Gross margin improved to 61.3% for the second quarter of 2026 from 60.4% in the second quarter of 2025.